Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD

Trial Details

NCT ID
NCT07238712
Phase
PHASE2
Sponsor
St. Petersburg State Pavlov Medical University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Ruxolitinib
  • Abatacept (Orencia)
Locations (sample)
  • Saint Petersburg, Russia|59.93863,30.31413

Key Eligibility Criteria

  • Patients with indication for allogeneic hematopoietic stem cell transplantation
  • Patients with \<10/10 HLA-matched related or unrelated donor available. The donor and recipient must be identical by the following genetic loci: HL…
  • Peripheral blood stem cells or bone marrow as a graft source
  • Diagnosis:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →